
Josefin Eklöf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8971463/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respiratory Medicine,the, 2019, 7, 699-709.	5.2	111
2	COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. BMJ Open Respiratory Research, 2019, 6, e000407.	1.2	47
3	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. European Respiratory Journal, 2022, 59, 2100752.	3.1	31
4	Use of inhaled corticosteroids and risk of acquiring <i>Pseudomonas aeruginosa</i> in patients with chronic obstructive pulmonary disease. Thorax, 2022, 77, 573-580.	2.7	26
5	Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease. Diabetes, Obesity and Metabolism, 2020, 22, 1348-1356.	2.2	19
6	Social Distancing in Relation to Severe Exacerbations of Chronic Obstructive Pulmonary Disease: A Nationwide Semi-Experimental Study During the COVID-19 Pandemic. American Journal of Epidemiology, 2022, 191, 874-885.	1.6	11
7	Antibiotic treatment adequacy and death among patients with Pseudomonas aeruginosa airway infection. PLoS ONE, 2019, 14, e0226935.	1.1	9
8	Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease. Clinical Microbiology and Infection, 2022, 28, 990-995.	2.8	9
9	Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials. Respiratory Research, 2021, 22, 155.	1.4	5
10	Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. International Journal of Infectious Diseases, 2021, 108, 370-376.	1.5	5
11	The Impact of Social Distancing in 2020 on Admission Rates for Exacerbations in Asthma: A Nationwide Cohort Study. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2086-2092.e2.	2.0	5
12	Systemic Corticosteroids and the Risk of Venous Thromboembolism in Patients with Severe COPD: A Nationwide Study of 30,473 Outpatients. Biomedicines, 2021, 9, 874.	1.4	4
13	Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid—data from 43,636 outpatients. Respiratory Research, 2021, 22, 11.	1.4	3
14	Depressive symptoms among patients with COPD according to smoking status: a Danish nationwide case–control study of 21â€S184 patients. ERJ Open Research, 2020, 6, 00036-2020.	1.1	3
15	The Association between Use of ICS and Psychiatric Symptoms in Patients with COPD—A Nationwide Cohort Study of 49,500 Patients. Biomedicines, 2021, 9, 1492.	1.4	3
16	Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms. PLoS ONE, 2022, 17, e0262898.	1.1	3
17	Roflumilast in Severely III Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations. Journal of Clinical Medicine, 2020, 9, 1442.	1.0	2
18	Risk of Chronic Obstructive Pulmonary Disease Exacerbation in Patients Who Use Methotrexate—A Nationwide Study of 58,580 Outpatients. Biomedicines, 2021, 9, 604.	1.4	2

#	Article	IF	CITATIONS
19	Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial. Respiratory Research, 2020, 21, 263.	1.4	1